Mahana Therapeutics acquires Cara Care, expands chronic condition treatment

Mahana Therapeutics has acquired Cara Care, a Berlin-based leader in digital digestive healthcare, aiming to bolster its position as a global leader in digital chronic condition management. The acquisition adds four digital treatment programs targeting significant populations to Mahana’s portfolio, including Irritable Bowel Syndrome (IBS), Irritable Bowel Disorder (IBD), Celiac Disease, and Heartburn, with plans to expand into Tinnitus, Pruritus, and Vulvodynia. Cara Care's IBS program, currently prescribed and reimbursed in Germany, is expected to accelerate Mahana’s market entry into Europe, particularly in France and the United Kingdom.

The merger combines Mahana’s and Cara Care's self-guided, digital chronic condition management programs employing proprietary cognitive behavioural therapy (CBT) platforms. These programs complement conventional treatments, potentially improving outcomes, patient satisfaction, and overall quality of life while reducing provider workload burden. Mahana sees the acquisition as an opportunity to reach millions of patients suffering from chronic conditions and plans to expand its distribution and partnership model, including collaborations with biopharmaceutical companies such as Bayer.

The combined company operates in the United States, Germany, and the United Kingdom, offering FDA-cleared and digital wellness programs for IBS and Tinnitus. Financial terms of the acquisition were not disclosed. Mahana Therapeutics is backed by prominent investors and aims to empower patients with chronic conditions to live fuller lives through its digital therapeutic programs.